Glenmark receives ANDA approval for Pimecrolimus Cream, 1%
30 August 2019 | News
It is a generic version of Elidel Cream, 1%, of Bausch Health US, LLC
Glenmark Pharmaceuticals has been granted final approval by the USFDA for Pimecrolimus Cream, 1%, a generic version of Elidel®1 Cream, 1%, of Bausch Health US, LLC.
According to IQVIATM sales data for the 12 month period ending July 2019, the Elidel® Cream, 1% market2 achieved annual sales of approximately $198.8 million.
Glenmark’s current portfolio consists of 160 products authorized for distribution in the U.S. marketplace and 55 ANDA’s pending approval with the USFDA.
